Buscar
Tenax Therapeutics Inc
TENXAñadir a la lista de seguimiento
14.520USD
+0.820+5.99%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
463.91MCap. mercado
PérdidaP/E TTM
Más Datos de Tenax Therapeutics Inc Compañía
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Información de Tenax Therapeutics Inc
Símbolo de cotizaciónTENX
Nombre de la empresaTenax Therapeutics Inc
Fecha de salida a bolsaOct 28, 1993
Director ejecutivoGiordano (Christopher T)
Número de empleados4
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 28
Dirección101 Glen Lennox Drive
CiudadCHAPEL HILL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27517
Teléfono19198552100
Sitio Webhttp://www.tenaxthera.com/
Símbolo de cotizaciónTENX
Fecha de salida a bolsaOct 28, 1993
Director ejecutivoGiordano (Christopher T)
Ejecutivos de Tenax Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Tenax Therapeutics Inc?
Los cinco principales accionistas de Tenax Therapeutics Inc son: Dr. Stuart Rich, M.D.
¿Cuántas instituciones poseen acciones de Tenax Therapeutics Inc (TENX)?
A fecha de 2026Q1, 74 instituciones poseen acciones de Tenax Therapeutics Inc, con un valor de mercado combinado de aproximadamente 11.71M, lo que representa el 51.15% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 5305648.00.